BULEVIRTIDE

Brand name:

• Hepcludex®

Pharmaceutical company:

Gilead Sciences Pty Limited

Condition/indication:
(therapeutic use)

• Chronic hepatitis D

PBAC Submission type:

New PBS listing (Category 1)

Comment:

--

Public Summary Document:

Not yet available

Related medicines:

--

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---